{"schema_version":"secwatch.filing_event.v1","accession":"0001510964-23-000022","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.166727+00:00","generated_at":"2026-06-15T01:04:36.845464+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CV Sciences Q1 revenue down 7% to $4.1M; gross margin improves to 43% vs 26% YoY","bullets":["Revenue $4.1M vs $4.4M YoY; sequential increase of 7% from Q4 2022.","Gross margin 43.0% vs 26.0% YoY; operating income $5.8M (incl. $6.2M payroll tax reversal).","Adjusted EBITDA loss narrowed to $0.2M from $2.5M YoY; cash balance $0.7M.","Received $2.5M employee retention credit; extinguished outstanding note in Q2 2023.","Maintained #1 hemp extract brand in natural product retail per SPINS; preliminary approval of shareholder derivative lawsuit settlement."],"urls":{"canonical":"https://secwatch.observer/filing/0001510964-23-000022","json":"https://secwatch.observer/filing/0001510964-23-000022.json","markdown":"https://secwatch.observer/filing/0001510964-23-000022.md","text":"https://secwatch.observer/filing/0001510964-23-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000151096423000022/0001510964-23-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000151096423000022/cvsi-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:04:36.845464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc2c94c5cd03642485b531a2592e18f8e664d85d","claim":"CV Sciences, Inc. reported the quarter ended March 31, 2023 results: revenue $4.1 million.","evidence_excerpt":"CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2023. First Quarter 2023 and Recent Financial and Operating Highlights • Generated revenue of $4.1 million for the first quarter 2023 compared to $4.4 million for first quarter 2022 and a sequential increase of 7% from $3.9 million in the fourth quarter 2022;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1510964/000151096423000022/0001510964-23-000022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$4.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}